Browse Articles

Discover research articles across all indexed journals

Rare earth stibolyl and bismolyl sandwich complexes

Nature Communications Noah Schwarz, Florian Bruder, Valentin Bayer et al. Feb 10, 2025 DOI: 10.1038/s41467-024-55474-6

Abstract The design of molecular rare earth complexes to achieve unique magnetic and bonding properties is a growing area of research with possible applications in advanced materials and molecular magnetics. Recent efforts focus on developing ligand frameworks that can enhance magnetic characteristics. Here we show the synthesis and characterization of a class of rare earth complexes, [(η5-C4R4Sb)Ln(η8-C8H8)] and [(η5-C4R4Bi)Ln(η8-C8H8)], featuring η5-coordinated stibolyl and bismolyl ligands. The ligand aromaticity and bonding situation within these complexes are investigated by quantum chemical calculations. Magnetic studies of the ErIII analogues reveal large barriers and intriguing properties, including waist-restricted hysteresis and slow relaxation of the magnetization, making them single-molecule magnets. Comparison between the experimental barrier and CASSCF-SO calculations indicates that relaxation in all systems occurs through high-energy excited states. These findings suggest that stibolyl and bismolyl ligands can be promising candidates for achieving high-energy barriers in Er-based SMMs, offering a pathway to molecular designs with enhanced magnetic properties.

Pharmacological and toxicological effects of Jiangfangbaoxin and determination of its components in the blood of spontaneously hypertensive rats

Scientific Reports Zhiqi Shi, Qing Wang, Fan Jia et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88009-0

Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC).

Journal of Clinical Oncology Chiara Mercinelli, Philippe E. Spiess, Roger Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.196

196 Background: CAPC is very challenging with significant need for improvement in systemic therapy, including for patients (pts) with incurable disease. Recently a novel HRDsig biomarker has been linked to clinical outcomes after PARP inhibitor-based treatments. We aimed to explore HRD sig status and related biomarkers, including other GA, to generate hypothesis and inform clinical trial designs for pts with CAPC. Methods: 22,061 cases of CAPC underwent comprehensive genomic profiling (CGP) to examine all classes of genomic alterations (GA). MSI high status, tumor mutation burden (TMB) levels, genomic ancestry and trinucleotide mutational signatures were determined from sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features.PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score (TPS) system. Results were compared using the Fisher exact system with the Benjamini-Hochberg adjustment to correct for false discovery. Results: Overall, 2,244 (10.2%) of CAPC cases were HRDsig+. There were slightly more MSI-high cases in the HRDsig- vs HRDsig+ CAPC (3.1% vs 0.5%; P<.0001). Both TMB and PD-L1 levels were low and varied in both groups. HRD associated GA included BRCA2 and RAD21 were more frequent in the CAPC HRDsig+ cases. BRCA1 GA were extremely rare in both groups. In the HRDsig- group, 90%/49% of BRCA1 / BRCA2 mutated CAPC were mono-allelic, likely non-driver GA, respectively Higher frequencies of GA in CDK12 and SPOP (11.1% vs 5.9%; P<.0001) were found in HRDsig- cases and a higher frequency of AR GA in HRDsig+ cases. MTOR pathway related GA in PTEN were similar, although homozygous deletions of PTEN were more frequent in the HRDsig- cases (22.2% vs 19.2%; P=.0009; Table). Conclusions: With a 10.2% frequency, HRDsig+ status is a relatively common biomarker in CAPC. HRDsig+ status was associated with a higher frequency of BRCA2 GA, including homozygous deletions in >20% of these pts, which has been associated with prolonged benefit from PARPi in selected pts. Given that likely non-driver mono-allelic BRCA1/2 GA are frequently identified in HRDsig- CAPC, mono-allelic GA may not be associated with HRDsig status and might not yield similar clinical benefit from PARPi. Limitations include the retrospective nature, potential selection bias and lack of clinical outcomes annotation. Main differences in GA classes between HRDSig- and HRDSig+. HRDSig- HRDSig+ P value Age (yrs) 68 70 <.0001 AFR ancestry 15.4% 13.1% 0.0110 AR 10.8% 17.3% <.0001 BRCA2 mutation 3.3% 52.3% <.0001 BRCA2 homozygous deletion 0.6% 21.4% <.0001 CDK12 5.5% 1.2% <.0001 RAD21 7.2% 16.3% <.0001 MMR sig 4.0% 2.0% <.0001 TMB≥10 mut/Mb 4.4% 3.7% NS

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

Journal of Clinical Oncology Jinchang Wei, Siming Li, Huayan Xu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.868

868 Background: Upper tract urothelial carcinoma (UTUC) presents distinct clinicopathological, molecular features, and biological behaviors compared to urothelial bladder carcinoma (UBC). Currently, no prognostic model exists for metastatic UTUC (mUTUC). This study aimed to develop a prognostic model for mUTUC patients receiving first-line systemic therapy. Methods: A total of 476 patients with mUTUC who received first-line systemic therapy at Peking University Cancer Hospital from January 2005 to March 2024 were included in the analysis. Patients were randomly assigned to development and validation cohorts in a 3:1 ratio, with potential prognostic factors recorded prospectively. Univariate Cox regression analysis identified clinical and laboratory factors significantly associated with median overall survival (mOS) in the development cohort, followed by multivariate Cox regression analysis to determine independent prognostic factors. These factors were utilized to develop a prognostic model. Internal validation was conducted using the validation cohort. Results: After a median follow-up of 51.8 months, 321 patients (67.4%) had died, with a mOS of 26.6 months. The median age at diagnosis was 63 years, with 58.4% males. Common visceral metastatic organs included lung (37.8%), liver (17.9%), and adrenal gland (7.4%). The most frequent first-line treatment option was platinum-containing chemotherapy (63.7%). The number of metastatic organs ≥ 3, Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 1, time to distant metastasis (TTDM) < 12 months, white blood cell (WBC) count > upper limit of normal (ULN), and alkaline phosphatase (ALP) level > ULN were identified as independent prognostic risk factors for mUTUC (Table). A prognostic model for mUTUC was developed, in which the patients were stratified into three risk categories: favorable (0 risk factors, mOS 65.0 months [95% CI 35.5–94.6]), intermediate (1 risk factor, mOS 32.0 months [95% CI 25.8–38.2]), and poor (2+ risk factors, mOS 16.0 months [95% CI 12.1–19.9]) ( p < 0.05). The model's concordance statistic (c-statistic) was 0.71 in the development cohort and 0.72 in the validation cohort. Conclusions: We developed and validated a prognostic model for mUTUC patients receiving first-line systemic therapy, which can inform future clinical practice and trial designs. Results of multivariate analysis. Variables P Hazard Ratio (95% CI) Reference Category TTDM <0.01 3.01 (2.13 ~ 4.26) ≥ 12 months ECOG PS <0.01 2.28 (1.30 ~ 3.97) ≤ 1 Number of Metastatic Organs 0.01 1.41 (1.04 ~ 1.91) < 3 WBC <0.01 1.89 (1.21 ~ 2.95) ≤ ULN ALP 0.02 1.71 (1.10 ~ 2.64) ≤ ULN

Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.

Journal of Clinical Oncology Alexander Giesen, Gaëtan Devos, Lorenzo Tosco et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.394

394 Background: High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence (BCR) and metastatic progression following local therapy. The ARNEO trial is a double-blind, placebo-controlled trial, evaluating the role of neoadjuvant degarelix with or without apalutamide before radical prostatectomy (RP) in men with high-risk PCa. Previously, we demonstrated that patients receiving neoadjuvant degarelix + apalutamide (n=45) had significantly better pathological response in terms of pT2 disease (51% vs. 27%; p=0.022) and minimal residual disease (MRD) (37.8% vs. 9.1%, p=0.002) compared to patients receiving degarelix alone (n=44). However, it was yet unclear if these improved pathological outcomes were also associated with improved oncological outcomes. Methods: High-risk PCa patients were randomly assigned 1:1 to degarelix + apalutamide versus degarelix + placebo for 12 weeks followed by radical prostatectomy. Follow-up of patients included PSA and testosterone testing every 6 months. No adjuvant radiotherapy was given. However, at time of PSA relapse (PSA >0.2 ng/ml) patients received a PSMA PET/CT. In case of negative imaging at time of BCR, patients received salvage radiotherapy to the prostate bed (+/- pelvic region). Results: All patients had a minimum follow-up of 36 months. Median follow-up was 46.5 months (IQR 42-53.5) in the degarelix + placebo arm and 46 months (IQR 42-53) in the degarelix + apalutamide arm. Median time to testosterone recovery (>50 ng/dl) was 6 and 7 months, respectively ( p = 0.15 ). In total, 14 (31%) patients in the degarelix + apalutamide arm developed BCR compared to 18 (41%) patients in the placebo arm (p=0.3). No statistically significant difference in BCR was observed between patients who achieved MRD and patients without MRD at final pathology (35% vs 38%; p = 1 ). However, ypT2 disease at final pathology was highly associated with improved BCR-free survival (11% vs 52%; p < 0.0001 ). Finally, we also looked at the prognostic value of achieving specimen-confined disease (SCD; defined as ypT2-3a AND negative surgical margins AND pN0). Patients with SCD at final pathology also had a significantly better BCR-free survival, compared to those patients without SCD (18% vs 65%; p < 0.0001 ). Conclusions: At 3 years follow-up, no statistically significant difference in terms of BCR was observed between patients treated with neoadjuvant degarelix + apalutamide or degarelix alone. MRD was not associated with improved BCR-free survival. However, ypT2 and SCD disease following neoadjuvant hormonal therapy was highly associated with improved BCR-free survival, suggesting that ypT2 and SCD disease might be used as a surrogate endpoints for improved BCR-free survival. Clinical trial information: NCT03080116 .

Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.

Journal of Clinical Oncology Andrew Leonard Laccetti, Matthew R Smith, Howard I. Scher et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.150

150 Background: Treatment of a BCR typically starts with androgen-deprivation therapy (ADT), which is limited by treatment-emergent adverse events (TEAEs) that adversely impact patients’ quality of life. The second-generation androgen receptor inhibitors (ARIs), enzalutamide and apalutamide, were explored in patients with BCR, demonstrating a reduction in prostate-specific antigen (PSA) but an increase in testosterone levels from baseline at week 25 of 114% and 134% (1,2). Given the strong efficacy and favorable tolerability of darolutamide, the open-label, phase 2 ARAMON study (NCT05526248) was conducted to investigate the reactive testosterone increase associated with darolutamide monotherapy in patients with CSPC after BCR. Here, we report lead-in phase results. Methods: Eligible patients had confirmed CSPC and a prior radical prostatectomy or radiotherapy, with a rising PSA doubling time ≤20 months, <5 asymptomatic metastatic lesions, serum testosterone >150 ng/dL, and ECOG performance status (PS) of 0/1. Patients received darolutamide 600 mg twice daily for 52 weeks. ADT was not allowed. The primary endpoint was the change in testosterone from baseline to week 12 and secondary endpoints of PSA response and TEAEs up to January 17, 2024 are also reported. Results: Of 23 evaluable patients, the median age was 74 (range, 54–84) years, the majority were white (n=14), had an ECOG PS of 0 (n=21), and Gleason score <8 (n=20). At study entry, the median PSA was 6.0 (range, 2.1–27.4) ng/mL, and most patients had nonmetastatic CSPC (n=15), 5 patients had oligometastatic disease (bone metastatic lesions <5), and 3 patients had soft tissue metastases (all <2 cm). At week 12, the mean percent increase in testosterone from baseline was 53% (95% CI, 33–76). Deep PSA responses to <0.2 ng/mL were observed in 15 patients at week 12. Feminizing TEAEs (gynecomastia, breast pain, breast tenderness, nipple pain, breast enlargement, breast mass, breast swelling, and hot flush) occurred in 18 patients and were grade 1 or 2 in 17 patients; 4 patients had dose modifications due to feminizing TEAEs and 2 patients received tamoxifen for gynecomastia. At week 12, none of the patients had discontinued darolutamide due to TEAEs. One patient discontinued darolutamide due to gynecomastia after week 12. Fatigue and hypertension occurred in 5 and 4 patients, all of which all events were grade 1/2 in severity. Conclusions: In patients with CSPC, darolutamide monotherapy increased baseline testosterone levels to a lesser degree than previously reported for other ARI agents administered as monotherapy and provided deep PSA responses at week 12. Darolutamide was well tolerated, with a low rate and severity of TEAEs. The ARAMON lead-in phase is limited by its single-arm, open-label design, and small sample size. 1. Tombal et al 2014. 2. Maluf et al 2021. Clinical trial information: NCT05526248 .

Non-catalytic mechanisms of KMT5C regulating hepatic gluconeogenesis

Nature Communications Qingwen Zhao, Xuan Cui, Qi Zhu et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56696-y

Longitudinal evaluation of the oral conditions of individuals with intellectual disabilities attending special Olympics events in Italy

Scientific Reports Daniela Carmagnola, Cristina Allievi, Dolaji Henin et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88729-3

Machine learning model integrating CT radiomics and circulating microRNAs to predict residual disease histology in metastatic non-seminoma testicular cancer (mNSTC).

Journal of Clinical Oncology Guliz Ozgun, Neda Abdalvand, Gizem Ozcan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.647

647 Background: The primary treatment of most mNSTC is chemotherapy followed by surgery if the residual disease (RD) is >1 cm. However, conventional imaging lacks the specificity to characterize the tissue, often leading to overtreatment. This study hypothesizes that integrating CT-driven radiomics features with plasma miR371 and miR375 will enhance the predictive accuracy of Machine Learning (ML) models to predict teratoma, viable germ cell (vGCT) and fibrosis/necrosis (F/N) in mNSTC patients with RD. Methods: 111 lesions from52 patients, including residual teratoma (n=57), F/N (n=33), vGCT (n=10), and additional seminoma (n=11) for training purposes were included, split into training (N=78) and test cohorts (N=33). Lesions were lymph nodes (n=87), lung (n=21), and brain (n=3) with a median size of 1.6 cm (Q1-Q3 interval=1.2-2.73 cm). 3D Slicer version 5.6.1 was used to segment the RD > 1 cm (short axis) and extract radiomics features. Plasma miRNA levels before resection were measured by RT-PCR. Random Forest (RF), Support Vector Machine (SVM), Gradient Boosting (GB), and CatBoost (CB) ML models were evaluated to define the operating characteristics of radiomics alone (R-only) and in combination with miR371 (371) and/or miR375 (375) levels in predicting teratoma, vGCT and F/N. Results: For predicting teratoma, the best models were RF (R+375 and R+371+375), CB (R+371+375), and GB (R+371 and R+371+375). While adding miR371 or miR375 to R-only slightly improved AUC across models, the best results were achieved with the R+375+371 dataset. CB achieved AUCs ranging from 0.94 to 0.97 in training and 0.81 to 0.93 in test sets, with its highest AUC of 0.93 (95% CI: 0.78-0.97) on the R+375+371 dataset to differentiate all three classes. Similarly, GB demonstrated strong performance, achieving its highest AUC of 0.93 (95% CI: 0.79-0.96) on the R+375+371 dataset (Table). Conclusions: Integration of plasma miR371, miR375 and radiomics improved accuracy of predicting histologies across all ML models. These methods could be used to characterize the histology of RD in mNSTC patients to better inform treatment decisions. Further refinement, including incorporation of histological findings of the primary tumor, will be reported. AUC values of different ML algorithms on training and test sets. TRAINING SET TEST SET Model ±SD R R+375 R+371 R+375+371 Model (95% CI) R R+375 R+371 R+375+371 RF 0.93±0.05 0.95±0.04 0.95±0.03 0.96±0.04 RF 0.8(0.59-0.89) 0.85(0.72-0.93) 0.87(0.76-0.95) 0.91(0.78-0.95) SVM 0.84±0.06 0.84±0.09 0.89±0.11 0.89±0.09 SVM 0.72(0.54-0.80) 0.74(0.56-0.82) 0.83(0.69-0.92) 0.84(0.76-0.94) GB 0.94±0.04 0.91±0.08 0.95±0.05 0.97±0.03 GB 0.84(0.61-0.96) 0.89(0.77-0.97) 0.89(0.79-0.96) 0.93(0.79-0.96) CB 0.95±0.03 0.94±0.03 0.94±0.04 0.97±0.03 CB 0.81(0.6-0.93) 0.86(0.73-0.94) 0.89(0.78-0.97) 0.93(0.78-0.97)

Evaluation of MIR-371A-3P for clinical implementation in a CLIA-certified laboratory.

Journal of Clinical Oncology Melis Gür, Kshitij Pandit, John T. Lafin et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.648

648 Background: MicroRNAs (mi-RNAs) have emerged as promising biomarkers for the detection of viable germ cell tumors (GCT). Our previous work in a research lab demonstrated optimal performance with positive results that had Cq values less than 28, an indeterminate range between 28-35 and negative results greater than 35. In this study, we assessed performance characteristics of miR-371a-3p in a CLIA certified lab at UCSD. Methods: Due to workflows, equipment and scaling, several modifications were required from our original research protocol. Ultimately, serum samples from 53 cases and 139 controls were analyzed using qPCR for miR-371a-3p in the CLIA lab. Initial runs and re-runs were conducted for the indeterminate samples. Metrics used for calculation of performance were sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the curve (AUC) and Youden’s index. Results: We used two analytic pipelines for classifying positive and negative Cq values: 1) a binary cutoff of 26.9 and, 2) an indeterminate range of 25.6 to 31.5. Using the binary cutoff, a sensitivity of 86%, specificity of 98%, PPV of 94%, NPV of 95%, AUC of 0.94 and Youden index of 0.85 was observed. In contrast, initial runs on the indeterminate ranges yielded a sensitivity of 95%, specificity of 99%, PPV of 97%, NPV of 98%, AUC of 0.97 and Youden index of 0.94. However, 36% (51 of 139) controls fell into the indeterminate range. Re-runs on these samples demonstrated similar findings. Conclusions: Our data demonstrated that there are likely lab specific, protocol specific and disease-state specific analytics and thresholding for circulating miR-371a-3p testing. These factors will need to be carefully considered while moving towards clinical implementation.

Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.

Journal of Clinical Oncology William C. Jackson, Robert Timothy Dess, Angela Y Jia et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.387

387 Background: Level 1 evidence supports treatment of high-risk and node positive PCa using 4-9 weeks of radiotherapy (RT) combined with 18-36 months of androgen deprivation therapy (ADT) with or without abiraterone acetate plus prednisone (AAP). While effective, some cancers recur, and this prolonged treatment is associated with inconvenience and variable morbidity. We aimed to determine whether the biological synergy of stereotactic body radiotherapy (SBRT) with a 6-month combination of ADT, AAP, and the PARP inhibitor niraparib, could enable a shorter intensified, yet safe and effective, therapeutic alternative. Methods: ASCLEPIuS (NCT04194554) is a multicenter investigator-initiated phase I/II trial in high-risk or node positive, homologous recombination unselected, PCa. Patients received 6 months of ADT, AAP, niraparib and SBRT to the prostate (37.5-40 Gy) +/- pelvic lymph nodes (25 Gy). Focal prostate/nodal boosting was permitted. The phase I primary endpoint was the maximum tolerated dose (MTD) of niraparib using the time-to-event continuous reassessment method (3 dose levels: 100 mg and 200 mg held during SBRT, or 200 mg concurrent with SBRT). Dose limiting toxicities (DLT) were any persistent grade 4+ hematologic toxicity or any grade 3+ rectal/urinary toxicity at least possibly related to treatment as assessed by CTCAE v5.0. Patient reported quality of life (QOL) was assessed with the EPIC-26 short form. Linear mixed models were used to compare scores over time. Results: Accrual began in Nov. 2020 with a transition from phase I to phase II in May 2023 after enrolling 54 men. Median follow-up of the phase I cohort is 12.1 months (IQR 9.4-18.9), 80% (n=43) had Grade Group 4-5, median PSA was 17 ng/mL (range, 1-73), 15% (n=8) had cN+ disease, and 76% (n=41) received nodal RT. There were 0 DLTs to date, no grade 3+ rectal or urinary toxicities, and 5 serious adverse events at least possibly attributable to study treatment (anemia, non-rectal gastrointestinal, syncope, infection, musculoskeletal). The most common grade 3 toxicities were hypertension (n = 11, 21%) and leukopenia (n=6, 11%). Transient dose reductions or holds of AAP or niraparib occurred in 10 and 11 patients, respectively. There were no statistically significant declines in patient reported urinary QOL at 6- or 12-months post-treatment compared to baseline (all p >0.15). A transient decline in bowel QOL at 6-months occurred (p<0.01), which improved by 12-months (p=0.16). Conclusions: Our phase I findings support the short-term safety and tolerability of the combination of SBRT to the prostate and nodes, ADT, AAP, and niraparib at an MTD of 200 mg in men with high-risk or node positive PCa. Our trial completed phase II enrollment in May 2024, and longer-term safety, efficacy, and genomic correlations will be presented in the future. Clinical trial information: NCT04194554 .

The impact of pelvic radiotherapy on hematological outcomes in pediatric genitourinary rhabdomyosarcoma.

Journal of Clinical Oncology Kamil Malshy, Zijin Cheng, Trevor C Hunt et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.379

379 Background: Hematological toxicities are common with radiation therapy (RT), particularly pelvic RT, which affects nearly 50% of total body hematopoiesis. This study evaluates the impact of pelvic RT on hematological toxicities in pediatric patients with pelvic genitourinary rhabdomyosarcoma (GU-RMS). Methods: Following permission, a secondary analysis was conducted on 488 pediatric subjects with intermediate-risk RMS from the ARST0531 (NCT00354835) trial. This trial compared Vincristine, Dactinomycin, and Cyclophosphamide (VAC) to VAC alternating with Vincristine and Irinotecan (VI). Both arms received RT starting in week 4. Of these, 65 patients had pelvic GU-RMS (bladder/prostate = 60 [92.3%]; female-organ = 2 [3.1%]; paratesticular = 3 [4.6%]) and received pelvic RT, while 423 received non-pelvic RT. Multivariable logistic regression models assessed hematological toxicities (anemia, leukopenia, neutropenia, thrombocytopenia, lymphopenia) during weeks 1–43, adjusting for age, race, tumor size, and chemotherapy. Primary outcomes included any hematological toxicity, and secondary outcomes focused on febrile neutropenia (FN), infectious complications (IC), and the timing of toxicity at T1 (weeks 1–15), T2 (weeks 16–30), and T3 (weeks 31–43). Results: Subjects with GU-RMS receiving pelvic RT did not have a significantly higher risk of cytopenias compared to non-GU RMS patients. Neutropenia affected 79.4% of patients, with no significant difference between GU (73.8%) and non-GU (80.4%) (OR 0.64, p=0.16). Thrombocytopenia was significantly more common in GU-RMS patients during the first 15 weeks (OR 2.79, p=0.01). FN and IC were comparable across groups. Conclusions: Hematological toxicities were similar in pediatric GU and non-GU RMS patients. Pelvic RT was linked to an early rise in thrombocytopenia, though the difference diminished over time. Understanding these toxicities is key to improving management of pediatric RMS patients. Patient characteristics and hematological toxicities outcomes: pelvic GU vs. non-GU primary. Parameter Overall Cohort, N (%)N = 488 GU, N (%)N= 65 (14.51) Non-GU, N (%)N = 383 (85.49) p-value < 10 y.o. 306 (68.30) 56 (86.15) 250 (65.27) 0.001 Male 241 (53.79) 48 (73.85) 193 (50.39) <0.001 White Race 319 (71.21) 48 (73.85) 271 (70.76) 0.487 Cytopenia OR (95% CI, p ) Anemia 159 (35.5) 24 (36.9) 135 (35.2) 0.96(0.54-1.70, 0.89) Thrombocytopenia 131(29.2) 22 (33.8) 109 (28.4) 1.49 (0.81-2.73, 0.20) Leukopenia 196 (43.75) 26 (40) 170 (44.4) 0.73 (0.42-1.27, 0.27) Neutropenia 356 (79.4) 48 (73.8) 308 (80.4) 0.64 (0.34-1.19, 0.16) Lymphopenia 105 (23.4) 15 (23.1) 90 (23.5) 0.85 (0.45-1.61, 0.61) GU – Genitourinary; OR – Odds Ratios.

Transdermal microneedle-assisted ultrasound-enhanced CRISPRa system to enable sono-gene therapy for obesity

Nature Communications Shaoyue Li, Jifeng Yu, Yuting Shen et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56755-4

ESM1 promote proliferation, invasion and angiogenesis via Akt/mTOR and Ras pathway in kidney renal clear cell carcinoma

Scientific Reports Jianjun Luo, Ting Yi, Yong Wang et al. Feb 10, 2025 DOI: 10.1038/s41598-024-82400-z

Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based regimen.

Journal of Clinical Oncology Daniel Sentana Lledo, Arjun Gupta, Carmine Rossi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.58

58 Background: Prior to ARPIs, chemotherapy was used to treat mCSPC. Recently, intensifying mCSPC treatment with a triplet combination of chemotherapy, ARPI and androgen deprivation therapy (ADT) has been a recommended approach. Few recent studies explore time burden and costs associated with chemotherapy-containing regimens (CCR) relative to non-chemotherapy containing regimens (NCR). This study compared the additive burden of docetaxel to ADT and ARPI combination by assessing the number of days needed to manage prostate cancer (PC) care and healthcare costs among patients with mCSPC receiving CCR or NCR in the US. Methods: Clinical data from community urology practices (PPS Analytics) linked with the Komodo Research Database (1/1/2016-12/31/2023) were used to identify patients initiating a CCR or NCR. The index date was earliest of ARPI or docetaxel initiation. Patients were followed from index until earliest of 12 months, ARPI discontinuation, start of new ARPI, chemotherapy initiation (NCR cohort only), or end of insurance/data availability. Outcomes reported per-patient-per-month (PPPM) included time spent managing mCSPC (total days with PC-related resource utilization [inpatient admissions, outpatient, emergency room, and other PC-related visits]) or PC management care (imaging, biopsy, chemotherapy management [iron/blood transfusions, erythropoiesis-stimulating agents, granulocyte colony-stimulating factor], testing), and all-cause and PC-related healthcare costs ($2023 US dollars). Cohorts were balanced on baseline covariates using overlap weighting. Outcomes were compared using weighted multivariable Poisson and linear regression models. Results: A total of 126 CCR and 837 NCR patients were identified (mean age 64.7 years, 52.6% White, 14.4% Black, and 33.7% had visceral metastasis in both cohorts). Patients were followed for a mean of 6.3 (CCR) and 6.8 (NCR) months. For the CCR cohort, a mean of 4.0 docetaxel infusions were observed per patient (mean time 22.0 days between infusions). The CCR cohort spent a mean of 4.1 days PPPM managing mCSPC, compared to 3.3 days PPPM in the NCR cohort (rate ratio: 1.18; 95% confidence interval [CI]; 1.03, 1.34). Mean all-cause medical and pharmacy costs were $17,833 PPPM in the CCR cohort and $11,527 PPPM in the NCR cohort (weighted adjusted cost difference [CD]: $6,184; 95% CI: 3,515, 8,517). Mean all-cause medical costs were $6,592 PPPM in the CCR cohort and $4,240 PPPM in the NCR cohort (CD [95% CI]: $2,060 [865, 3,369]). Conclusions: In this real world study, patients initiating a CCR experienced greater time toxicity managing mCSPC and higher healthcare costs than those initiating an NCR. Counseling expressing these differences in burden should be included in decision-making conversations when selecting treatment for mCSPC.

Validation of a 15-gene prognostic signature in metastatic clear cell renal cell carcinoma.

Journal of Clinical Oncology Steven Monda, Srinivas Nallandhighal, Ulka N. Vaishampayan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.578

578 Background: Our group previously developed and validated a 15-gene prognostic signature (15G score) in localized clear cell renal cell carcinoma (ccRCC). Giving its ability to differentiate aggressive and indolent disease in the localized setting, we sought to apply the 15G score to patients with metastatic ccRCC to evaluate the 15G score’s prognostic performance across different treatments. Methods: We analyzed 2,121 patients from four major metastatic ccRCC trial datasets: IMmotion 150 (IMM150), Immotion 151 (IMM151), Javelin Renal 101 (JR101), and Checkmate 009, 010, and 025 (CM009/010/025). Treatment and control arms from all trials were included and grouped within treatment groups which included atezolizumab, atezolizumab plus bevacizumab, sunitinib, avelumab plus axitinib, nivolumab, and everolimus. The 15G score, originally derived and established to be prognostic in localized ccRCC, was calculated using z-score transformed RNA-seq data from each arm of the included trials to classify patients into high-risk versus low-risk using a previously derived threshold. We tested the association of 15G score high-risk with progression free survival (PFS) in each treatment group using Cox proportional hazards analyses with and without controlling for MSKCC risk. Results: On univariable Cox analysis, a 15G high-risk score was associated with significantly worse PFS in five of the seven treatment groups (Table). Worse PFS was observed for atezolizumab, atezolizumab plus bevacizumab, sunitinib, and everolimus (HR [95% CI]: 2.8 [1.6-4.9],1.7 [1.4-2.2], 1.7 [1.4-2.0], and 1.5 [1.1-2.2]. Within IMM151 and CM009/010/025, where risk group data were available, 15G score high-risk was independently associated with worse PFS while controlling for MSKCC risk group for atezolizumab plus bevacizumab, sunitinib, and everolimus (HR [95% CI]: 1.5 [1.2-2.0], 1.7 [1.4-2.2], 1.6 [2.3], p<0.05). Within CM009/010/025, where overall survival (OS) data were available, 15G score high-risk was associated with worse OS for everolimus (HR [95% CI]: 1.5 [1.0-2.2]) but did not reach significance for nivolumab (HR [95% CI]: 1.4 [0.9-2.0]). Conclusions: The 15G score was independently prognostic in metastatic ccRCC among a diverse cohort of patients receiving different systemic therapy regimens. PFS associated with 15G score high-risk compared to low-risk from univariable Cox analysis within each treatment group. Treatment Group Trials 15G scoreLow-risk (n) 15G scoreHigh-risk (n) p-value PFS HR (95% CI) Immunotherapy Atezolizumab IMM150 45 41 <0.001 2.8(1.6, 4.9) Nivolumab CM009/010/025 74 106 0.06 1.4(1.0, 1.9) Combination Atezolizumab+Bevacizumab IMM151/150 218 277 <0.001 1.7(1.4, 2.2) Avelumab+Axitinib JR101 152 202 0.09 1.3(1.0, 1.8) TKI / MTORi Sunitinib IMM150/IMM151/JR101 370 507 <0.001 1.7(1.4, 2.0) Everolimus CM009/010/025 51 78 0.03 1.5(1.1, 2.2)

Molecular evolution of HRR gene alterations in metastatic prostate cancer: A ctDNA-based study.

Journal of Clinical Oncology Chinmay Jani, Eli Tran, Nicole Zhang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.255

255 Background: Homologous recombination repair (HRR) genes, including DNA repair genes, are increasingly recognized for impacting treatment resistance and prognosis of metastatic prostate cancer (mPC). Next-generation sequencing of circulating tumor DNA (ctDNA) enables non-invasive, longitudinal monitoring of molecular alterations in patients (pts) undergoing systemic therapies. This study explores the dynamic changes in ctDNA profiles in mPC, particularly focusing on the HRR alterations. Methods: We utilized GuardantINFORM, a clinical-genomics database containing de-identified ctDNA test results and commercial payer-claims data. Eligible pts had a diagnosis of mPC and underwent ctDNA testing pre (within 3 months before initiation) and post (within 3 months of discontinuation before initiating subsequent treatment) Androgen Receptor Pathway Inhibitors (ARPi), poly ADP-ribose polymerase inhibitors (PARPi), and taxane chemotherapy. Mann-Whitney test assessed the differences in mutations. We also examined the association between ctDNA burden and overall survival (OS). Results: From a database of 21,682 pts with mPC, 145 had ctDNA collected pre/post-ARPi, 54 pre/post PARPi and 115 pre/post taxane chemotherapy. Pre-to-post-ARPI, individual HRR alterations increased from 21 to 34, with the most common (%pre/%post) genes to be altered, including ATM (5.5/7.6), BRCA2 (3/6) and CDK12 (3/2). In the PARPi group, the most prevalent (%pre/%post) genes to be altered were ATM (28/22), BRCA2 (28/20) and BRCA1 (4/6). Although overall BRCA2 prevalence declined, 11 new unique alterations were detected post-PARPi, along with an increase in unique BRCA1 (2 to 4) and BRCA2 (16 to 21) alterations. Three of 25 patients (12%) who underwent serial testing pre- and post-PARPi exhibited BRCA reversion mutations. In the taxane group, notable (%pre/%post) HRR genes to be altered included ATM (4/3), BRCA1 (1/3), and BRCA2 (1/3). Patients with higher ctDNA burden in pre-treatment samples exhibited worse OS. Conclusions: This study reveals dynamic changes in HRR gene alterations in mPC using ctDNA profiling. We observed increased unique alterations in ATM, BRCA1, and BRCA2 post-treatment, along with BRCA reversion mutations, indicating potential treatment resistance mechanisms. These findings underscore the importance of tailoring therapeutic approaches based on HRR gene profiles in mPC.

Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.

Journal of Clinical Oncology Hannah Dzimitrowicz McManus, Lauren Howard, Kerri-Anne Crowell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.65

65 Background: Intensified androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPI) and/or docetaxel has led to improved outcomes for metastatic hormone-sensitive prostate cancer (mHSPC) in multiple clinical trials. Achievement of an undetectable PSA nadir has been associated with improved clinical outcomes, but real-world data across treatment regimens are limited. Methods: We evaluated PSA response and outcomes for patients with mHSPC treated with ADT monotherapy (mono), ADT + ARPI, and ADT + docetaxel in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). All patients with mHSPC enrolled in IRONMAN between 2017 and August 2023 in the United States, Canada, Spain, and England were included. Patients treated with triplet therapy were excluded due to small numbers. Undetectable PSA nadir, defined as PSA <0.2 ng/mL, was evaluated at 6 and 12 months after treatment start. In this real-world study, relapse was defined as meeting one of the following criteria: PSA progression (≥25% PSA increase from nadir and absolute increase >2 ng/mL), treatment change preceded by new metastasis location, or change to a neuroendocrine prostate cancer regimen. Rates of relapse were calculated using Kaplan Meier estimates, with confidence intervals based on standard errors calculated using the Greenwood formula. Results: Among 1,377 eligible patients, treatment was most commonly ADT + ARPI (n=775) followed by ADT mono (n=375) and ADT + docetaxel (n=227). In the overall population, PSA nadir <0.2 ng/mL was achieved in 40% (n=554) at 6 months and 51% (n=702) at 12 months. Rates of PSA nadir <0.2 ng/mL at 6 months were: 51% for ADT + ARPI, 27% for ADT mono, and 26% for ADT + docetaxel. At 12 months, rates of PSA nadir <0.2 ng/mL increased to: 63% for ADT + ARPI, 38% for ADT mono, and 32% for ADT + docetaxel. During a median follow-up of 18 months, 291 patients (21%) experienced disease relapse; 19% experienced PSA progression. The percentage of patients in each treatment group with disease relapse at months 12, 24, and 36 of treatment are shown (Table); treatment groups are divided by whether patients had achieved PSA nadir <0.2 ng/mL in 6 months. Conclusions: In this non-randomized, real-world registry, patients with mHSPC who achieved a PSA nadir <0.2 ng/mL had a lower relapse rate than patients who did not, regardless of treatment. Percentage (95% CI), [number at risk] of patients with relapse at timepoint. Treatment Month 6 Month 12 Month 24 Month 36 ADT Monotherapyn=375 PSA <0.2 ng/mL 0%(0, 0)[60] 1.7%(0, 5.0)[31] 11%(0, 24)[15] PSA ≥0.2 ng/mL 18%(11, 24)[80] 41%(30, 51)[38] 45%(33, 55)[19] ADT + ARPIn=775 PSA <0.2 ng/mL 2.2%(0.6, 3.8)[288] 9.7%(5.9, 13)[166] 18%(12, 24)[76] PSA ≥0.2 ng/mL 21%(16, 26)[178] 42%(35, 49)[81] 50%(42, 58)[37] ADT + Docetaxeln=227 PSA <0.2 ng/mL 8.2%(0.2, 16)[44] 22%(8.9, 33)[29] 36%(18, 50)[14] PSA ≥0.2 ng/mL 34%(25, 43)[69] 62%(50, 72)[21] 73%(59, 82)[12]

Thermal processing to modulate surface chemistry and bulk charge distribution in nickel-rich layered lithium positive electrodes

Nature Communications Huabin Sun, Zhijie Yang, Rupayan Ghosh et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56075-7

Robust pose estimation for non-cooperative space objects based on multichannel matching method

Scientific Reports Zhaoxiang Zhang, Yuelei Xu, Jianing Song Feb 10, 2025 DOI: 10.1038/s41598-025-89544-6